川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的临床观察

Clinical Observation of Ligustrazine Injection,α-ketoacid Combined with Levamlodipine in the Treatment of Chronic Renal Failure

目的:观察川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的疗效和安全性。方法:92例慢性肾功能衰竭患者随机分为观察组(46例)和对照组(46例)。所有患者均给予电解质、维生素及氨基酸、低盐低脂、降糖降脂、抗感染及纠正贫血等常规对症治疗。在此基础上,对照组患者口服复方α-酮酸片8片,每日3次+苯磺酸左旋氨氯地平片1片,每日1次。观察组患者在对照组治疗的基础上给予盐酸川穹嗪注射液150mg,加入5%葡萄糖250ml中,静脉滴注,每日1次。两组疗程均为3个月。观察两组患者的临床疗效,治疗前后尿素氮(BUN)、血肌酐(Scr)、血清胱抑素(CysC)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、三酰甘油(TG)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者BUN、Scr、CysC、LDL-C、TC、TG比较,差异均无统计学意义(P>0.05)。治疗后,两组患者BUN、Scr、LDL-C、TC、TG均显著低于同组治疗前,且观察组低于对照组,CysC显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的疗效显著,可改善肾功能,且安全性较好。

OBJECTIVE:To observe the clinical efficacy and safety of Ligustrazine injection,α-ketoacid combined with levamlodipinein the treatment of chronic renal failure. METHODS:92 patients with chronic renal failure were randomly divided into observationgroup(46 cases)and control group(46 cases). All patients received electrolyte,vitamins and essential amino acid,lowsalt,low fat,hypoglycemic and hypolipemic,anti-infection,correcting anemia and other conventional symptomatic treatment.Based on it,control group received 8 Compound α-ketoacid tablets,3 times a day + 1 Benzenesulfonic acid levamlodipine tablet,once a day. Observation group additionally received 150 mg Ligustrazine hydrochloride injection,adding into 250 ml 5% Glucoseinjection,intravenous infusion,once a day. The treatment course for both groups was 3 months. Clinical efficacy,and urea nitrogen(BUN),serum creatinine (Scr),serum cystatin (CysC),low-density lipoprotein cholesterol (LDL-C),total cholesterol(TC),triglyceride(TG)levels before and after treatment and the incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically significant(P<0.05). Before treatment,there were no significant differences in the BUN,Scr,CysC,LDL-C,TC and TG between2 groups(P>0.05). After treatment,BUN,Scr,LDL-C,TC and TG in 2 groups were significantly lower than before,and observationgroup was lower than control group,CysC was significantly higher than before,and observation group was higher than controlgroup,the differences were statistically significant(P<0.05). And there was no significant difference in the incidence of adversereactions(P>0.05). CONCLUSIONS:Based on conventional treatment,Ligustrazine injection,α-ketoacid combined with levamlodipineshow obvious efficacy in the treatment of chronic renal failure,they can improve the renal functions,with good safety.